Respiratory syncytial virus-induced immunoprotection and immunopathology

Viral Immunology

Volumn 17, Issue 3, 2004, Pages 370-380

  Durbin, Joan E ^a,b   Durbin, Russell K ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; GLYCOPROTEIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; RANTES; RESPIRATORY SYNCYTIAL VIRUS VACCINE; TOLL LIKE RECEPTOR 4; VACCINE; VIRUS ANTIGEN;

CORRELATION ANALYSIS; DRUG MECHANISM; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; IMMUNOPATHOLOGY; NONHUMAN; PARAMYXOVIRUS; PATHOLOGY; PNEUMONIA; PNEUMOVIRINAE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; T LYMPHOCYTE; TH1 CELL; TH2 CELL; VIRUS INFECTION; VIRUS REPLICATION;

ANIMALS; HUMANS; IMMUNITY, NATURAL; INTERFERON TYPE II; INTERLEUKIN-13; KILLER CELLS, NATURAL; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; RECEPTORS, CELL SURFACE; RECEPTORS, CHEMOKINE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; T-LYMPHOCYTES, CYTOTOXIC; TOLL-LIKE RECEPTORS; VIRAL PROTEINS;

PARAMYXOVIRIDAE; PNEUMOVIRINAE; PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS; RNA VIRUSES;

EID: 4544365736     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2004.17.370     Document Type: Review

References (123)

1. Alcami, A. 2003. Viral mimicry of cytokines, chemokines and their receptors. Nat. Rev. Immunol. 3:36-50.
2. Antonis, A., R. Schrijver, F. Duas, et al. 2003, Vaccine-induced immunppathology during bovine respiratory syncytial virus infection: exploring the parameters of pathogenesis. J. Virol. 77:12067-12073.
3. Atkins, J., P. Karimi, B. Morris, et al. 2000. Prophylaxis for RSV with RSV-immunoglobulin intravenous among preterm infants of thirty-two weeks gestation and less: reduction in incidence, serverity of illness, and cost. Pediatr. Infect. Dis. J. 19:138-143.
4. Atreya, P., and S. Kulkarni. 1999. RSV strain A2 is resistant to the antiviral effects of type I interferons and human MxA. Virology 261:227-241.
5. Aung, S., and B.S. Graham. 2000. Interleukin-4 diminishes perforin-mediated and increases fas ligand-mediated cytotoxicity in vivo. J. Immunol. 164:3487-3493.
6. Aung, S., J.A. Rutigliano, and B.S. Graham. 2001. Alternative mechanisms of respiratory syncytial virus clearance in perform knockout mice lead to enhanced disease. J. Virol. 75:9918-24.
7. Barnes, B., B. Lubyova, and P. Pitha. 2002. On the role of IRF in host defense. J. Interferon Cytokine Res. 22: 59-71.
8. Barr, F., H. Pedigo, T. Johnson, et al. 2000. Surfactant protein-A enhances uptake of RSV by monocytes and U937 macrophages. Am. J. Respir. Cell Mol. Biol. 23: 586-592.
9. Biron, C., K. Nguyen, G. Pien, et al. 1999. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu. Rev. Immunol. 17:189-220.
10. Biron, C.A. 1998. Role of early cytokines, including alpha and beta interferons, in innate and adaptive immune responses to viral infections. Semin. Immunol. 10:383-390.
11. Blanco, J., J. Richardson, M. Darnell, et. al. 2002. Cytokine and chemokine gene expression after primary and secondary RSV infection in cotton rats. J. Infect. Dis. 185: 1780-1785.
12. Boelen, A., J. Kwakkel, M. Barends, et al. 2002. Effect of lack of IL-4, IL-12, IL-18, or the IFN-gamma receptor on virus replication, cytokine response and lung pathology during RSV infection in mice. J. Med. Virol. 66: 552-560.
13. Bont, L., J. Versteegh, W. Swelsen, et al. 2002. Natural reinfection with respiratory syncytial virus does not boost virus-specific T-cell immunity. Pediatr. Res. 52:363-367.
14. Bessert, B., S. Marozin, and K.-K. Conzelmann. 2003. Nonstructural proteins NS1 and NS2 of bovine respiratory syncytial virus block activation of Interferon regulatory factor 3. J. Virol. 77:8661-8668.
15. Brandenberg, A., A. Kleinjan, B. van het Land, et al. 2000. Type-1-like immune response is found in children with RSV infection regardless of clinical severity. J. Med. Virol. 62:267-277.
16. Cannon, M.J., P.J.M. Openshaw, and B.A. Askonas. 1988. Cytotoxic T lymphocytes clear virus but augment lung pathology in mice infected with RSV. J. Exp. Med. 168: 1163-1168.
17. + memory in the respiratory tract. Nat. Med. 8:54-60.
18. + T cells during experimental virus infection. J. Immunol. 167:4254-4260.
19. Chin, J., R.L. Magoffin, L.A. Shearer, et al. 1969. Field evaluation of a RSV vaccine and a trivalent parainfluenxa virus vaccine in a pediatric population. Am. J. Epidemiol. 89:449-463.
20. Cole, K., C. Strick, M. Loetscher, et al. 1998. Interferon inducible T-cell alpha chemoattractant (I-TAC): a novel non-ELR chemokine with potent activity on activated T-cells through sleective high affinity binding to CXCR3. J. Exp. Med. 187:2009-2021.
21. + T cells. J. Virol. 66:7444-7451.
22. Dakhama, A., T. Vitalis, and Kegele, R.G. 1997. Persistence of RSV infection and development of RSV-specific IgGl response in a guinea-pig model of acute bronchiolitis. Eur. Respir. J. 10:20-26.
23. de Swart, R., T. Kuilen, H. Timmerman, et al. 2002. Immunization of macaques with formalin-inactivated respiratory syncytial virus (RSV) induces interleukin-13-associated hypersensitivity to subsequent RSV infection. J. Virol. 76:11561-11569.
24. Domachowske, J., C. Bonville, and H. Rosenberg. 2001. Gene expression in epithelial cells in response to pneumovirus infection. Respir. Res. 2:225-233.
25. Durbin, J.E., T.R. Johnson, R.K. Durbin, et al. 2002. The role of interferon in respiratory syncytial virus pathogenesis. J. Immunol. 168:2944-2952.
26. Ehl, S., R. Bischoff, T. Ostler, et al. 2004. The role of Toll-like receptor 4 versus IL-12 in immunity to RSV. Eur. J. Immunol. 34:1146-1153.s
27. Falsey, A. 1998. Respiratory syncytial virus infection in older persons. Vaccine 16:1775-1778.
28. Falsey, A., and E. Walsh. 1998. Relationship of serum antibody to risk of RSV infection in elderly adults. J. Infect. Dis. 177:463-466.
29. Fraticelli, P., M. Sironi, G. Bianch, et al. 2001. Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J. Clin. Invest. 107:1173-1181.
30. Fulginiti, V.A., J.J. Eller, O.P. Sieber, et al. 1969. Respiratory virus immunization, I: a field trial of two inactivated respiratory virus vaccines, an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am. J. Epidemiol. 89: 435-448.
31. alpha (not T helper type 2 cytokines) is associated with severe forms of respiratory syncytial virus bronchiolitis. J. Infect. Dis. 184:393-399.
32. Ghidyal, R., C. Hartley, A. Varrasso, et al. 1999. Surfactant protein A binds to the fusion glycoprotein of RSV and neutralizes virion infectivity. J. Infect. Dis. 180: 2009-2013.
33. Glezen, P., and F. Denny. 1973. Epidemiology of acute lower respiratory disease in children. N. Eng. J. Med. 288: 498-505.
34. Glezen, W., A. Paredes, J. Allison, et al. 1986. Risk of primary infection and reinfection with RSV. Am. J. Dis. Child. 140:543-546.
35. Goodbourn, S., Didcock, L, and Randall, R.E. 2000. Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. J. Gen. Virol. 81: 2341-2364.
36. Gotoh, B., T. Komatsu, K. Takeuchi, et al. 2002. Paramyxovirus strategies for evading the interferon response. Rev. Med. Virol. 12:337-357.
37. Graham, B., L. Bunion, J. Rowland,.et al. 1991. RSV infection in anti-mu-treated mice. J. Virol. 65:4936-4942.
38. Graham, B.S., L.A. Bunton, P.P. Wright, et al. 1991. The role of T cell subsets in the pathogenesis of primary infection and reinfection with RSV in mice. J. Clin. Invest. 88:1026-1033.
39. Graham, B.S., O.S. Henderson, Y.-W. Tang, et al. 1993. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with RSV. J. Immunol. 151:2032-2040.
40. Graham, B.S., M.D. Perkins, P.P. Wright, et al. 1988. Primary RSV infection in mice. J. Med. Virol. 26:153-162.
41. T.I.R.s. Group. 1998. Reduction of RSV hospitalization among premature infants and infants with bronchopulmonary dysplasia using RSV monoclonal antibody prophylaxis. Pediatrics 102:531-537.
42. Haeberle, H., W. Kuziel, H. Dieterich, et al. 2001. Inducible expression of inflammatory chemokines in RSV-infected mice: role of MIP-1α in lung pathology. J. Virol. 75:878-890.
43. Hall, C. 2001. Respiratory syncytial virus and parainfluenza virus. N. Engl. J. Med. 344:1977-1978.
44. Hall, C., Douglas, R.G, and J. Geiman. 1976. RSV infections in infants: quantitation and duration of shedding. J. Pediatr. 89:11-15.
45. Hall, C.B. 1998. Respiratory syncytial virus, pp. 2084-2111. In: R.D. Feigen and J.D. Cherry (ed.), Textbook of Pediatric Infectious Disease, 4th ed. W.B. Saunders, Philadelphia.
46. Hall, C.B., C.E. Long, and K.C. Schnabel. 2001. Respiratory syncytial virus infections in previously healthy working adults. Clin. Infect. Dis. 33:792-796.
47. Hancock, G.E., D.I. Speelman, K. Heers, et al. 1996. Generation of atypical pulmonary inflammatory responses in Balb/c mice after immunization with the native attachment (G) glycoprotein of RSV. J. Virol. 70:7783-7791.
48. Hatada, E., D. Krappmann, and C. Scheidereit. 2000. NF-kappaB and the innate immune response. Curr. Opin. Immunol. 12:52-58.
49. Haynes, L., D. Moore, E. Kurt-Jones, et al. 2001. Involvement of Toll-like receptor 4 in innate immunity to respiratory syncytial virus. J. Virol. 77:10730-10737.
50. He, B., R. Paterson, N. Stock, et al. 2002. Recovery of paramyxovirus simian virus 5 with a V protein lacking the conserved cysteine-rich domain: the multifunctional V protein blocks both interferon-beta induction and interferon signaling. Virology 303:15-32.
51. Heikkinen, T., M. Thint, and T. Chonmaitree. 1999. Prevalence of various respiratory viruses in the middle ear during acute otitis media. Pediatrics 104:419-427.
52. Henderson, F., A. Collier, W. Clyde, et al. 1979. RSV infections, reinfections, and immunity. A prospective, longitudinal study, in young children. N. Engl. J. Med. 300: 530-534.
53. Hendricks, D., K. McIntosh, and J. Patterson. 1988. Further characterization of the soluble form of the G glycoprotein of respiratory syncytial virus. J. Virol. 62: 2228-2233.
54. Hickling, T., H. Bright, K. Wing, et al. 1999. A recombinant trimeric surfactant protein D carbohydrate recognition domain inhibits RSV infection in vitro and in vivo. Eur. J. Immunol. 29:3478-3484.
55. Hiscott, I., N. Grandvaux, S. Sharma, et al. 2003. Convergence of the NF-kappaB and interferon signaling pathways in the regulation of antiviral defense and apoptosis. Ann. NY Acad. Sci. 1010:237-248.
56. + T cells persist in the lungs following recovery from respiratory virus infection. J. Immunol. 166:1813-1822.
57. + T cells control Th2-driven pathology during pulmonary RSV infection. Eur. J. Immunol. 27:3341-3349.
58. Hussell, T., and P. Openshaw. 2000. IL-12-activated NK cells reduce lung eosinophilia to the attachment protein of RSV but do not enhance the severity of illness in CDS T cell-immunodeficient conditions. J. Immunol. 165: 7109-7115.
59. Hussell, T., and P.J.M. Openshaw. 1998. Intracellular IFN-gamma expression in natural killer cells precedes lung CD8 T cell recruitment during RSV infection. J. Gen. Virol. 79:2593-2601.
60. Hussell, T., L. Spender, A. Georgiou, et al. 1996. Th1 and Th2 cytokine induction in pulmonary T cells during infection with respiratory syncytial virus. J. Gen. Virol. 77: 2447-2455.
61. Johnson, T., and B. Graham. 2004. Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during the primary respiratory syncytial virus infection. Pediatr. Infect. Dis. J. 23:S46-S57.
62. Kalina, W., A. Woolums, R. Berghaus, et al. 2004. Formalin-inactivated bovine RSV vaccine enhances a Th2-mediated immune response in infected cattle. Vaccine 22: 1465-1474.
63. Kapikian, A.A., R.H. Mitchell, R.M. Chanock, et al. 1969. An epidemiologic study of altered clinical reactivity to RSV infection in children previously vaccinated with an inactivated RSV vaccine. Am. J. Epidemiol. 89:405-421.
64. Katze, M., Y. He, and M. Gale, Jr. 2002. Viruses and Interferon: a fight for supremacy. Nat. Rev. Immunol. 2:675-687.
65. Kim, H.W., J.G. Canchola, C.D. Brandt, et al. 1969. RSV disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89:422-434.
66. Komiya, A., H. Nagase, H. Yamada, et al. 2003. Concerted expression of eotaxin-1, eotaxin-2, and eotaxin-3 in human bronchial epithelial cells. Cell. Immunol. 225:91-100.
67. Kurt-Jones, E., L. Popova, L. Kwinn, et al. 2000. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat. Immunol. 1:398-401.
68. Lahti, M., J. Lofgren, R. Marttila, et al. 2002. Surfactant protein D gene polymorphism associated with severe RSV virus infection. Pediatr. Res. 51:696-699.
69. Langedijk, J., B. de Groot, H. Berendsen, et al. 1998. Structural homology of the central conserved region of the attachment protein G of respiratory syncytial virus with the fourth subdomain of 55-kDa tumor necrosis factor receptor. Virology 243:293-302.
70. Le Bon, A., and D. Tough. 2002. Links between innate and adaptive immunity via type I interferon. Curr. Opin. Immunol. 14:432-436.
71. LeBon, A., G. Schiavoni, G. D' Agostino, et al. 2001. Type I Interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14:461-470.
72. Legg, J., I. Hussain, J. Warner, et al. 2003. Type I and type 2 cytokine imbalance in acute RSV bronchiolitis. Am. J. Respir. Crit. Care Med. 168:633-639.
73. LeVine, A., J. Elliot, J. Whitsett, et al. 2004. Surfactant protein-D enhances phagocytosis and pulmonary clearance of RSV. Am. J. Respir. Cell. Mol. Biol. 31:193-199.
74. LeVine, A., J. Gwozdz, J. Stark, et al. 1999. Surfactant protein-A enhances RSV clearance in vivo. J. Clin. Invest. 103:1015-1021.
75. Levine, S., R. Klaiber-Franco, and P. Paradiso. 1987. Demonstration that glycoprotein G is the attachment protein of respiratory cyncytial virus. J. Gen. Virol. 68: 2521-2524.
76. Loetscher, M., B. Gerber, P. Loetscher, et al. 1996. Chemokine receptor specific for IP-10 and Mig: structure, function, and expression in activated T-lymphocytes. J. Exp. Med. 184:963-969.
77. Lofgren, J., M. Ramet, M. Renko, et al. 2002. Association between surfactant protein A gene locus and severe RSV infection in infants. J. Infect. Dis. 185:283-289.
78. Luster, A., J. Unkeless, and J. Ravetch. 1985. Gamma-interferon transcription regulates an early-response gene containing homology to platelet proteins. Nature 315: 672-676.
79. Mackay, C. 2001. Chemokines: immunology's high impact factors. Nat. Immunol. 2:95-99.
80. Mathew, A., B. Medoff, A. Carafone, et al. 2002. Cutting edge: Th2 cell trafficking into the allergic lung is dependent on chemoattractant receptor signaling. J. Immunol. 169:651-655.
81. Neilson, K., and E. Yunis. 1990. Demonstration of RSV in an autopsy series. Pediatr. Pathol. 10:491-502.
82. Neuzil, K.M., J.E. Johnson, Y.-W. Tang, et al. 1997. Adjuvants influence the quantitative and qualitative immune response in balb/c mice immunized with RSV FG subunit vaccine. Vaccine 15:597-602.
83. Niewiesk, S., and G. Prince. 2002. Diversifying animal models: the use of hispid cotton rats (Sigmodon hispidus) in infectious diseases. Lab. Anim. 36:357-372.
84. Openshaw, P., S. Clarke, and F. Record. 1992. Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G. Int. Immunol. 4:493-500.
85. Openshaw, P., R. Pemberton, L. Ball, et al. 1988. Helper T cell recognition of RSV in mice. J. Gen. Virol. 69: 305-312.
86. Openshaw, P.J., K. Anderson, G.W. Wertz, et al. 1990. The 22,000-kilodalton protein of respiratory syncytial virus is a major target for Kd-restricted cytotoxic T lymphocytes from mice primed by infection. J. Virol. 64: 1683-1689.
87. Ostler, T., T. Hussell, C. D. Surh, et al. 2001. Long-term persistence and reactivation of T cell memory in the lung of mice infected with respiratory syncytial virus. Eur. J. Immunol. 31:2574-2582.
88. Palucka, K., and J. Banchereau. 2002. How dendritic cells and microbes interact to elicit or subvert protective immune responses. Curr. Opin. Immunol. 14:420-431.
89. Paramore, L., V. Ciuryla, G. Cisela, et al. 2004. Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases. Pharmacoeconomics 22:275-284.
90. Peebles, R., K. Hashimoto, R. Collins, et al. 2001. Immune interactions between RSV infection and allergen sensitization critically depends on timing of challenges. J. Infect. Dis. 184:1374-1379.
91. Peebles, R., K. Hashimoto, and B. Graham. 2003. The complex relationship between RSV and allergy in lung disease. Viral Immunol. 16:25-34.
92. Pemberton, R.M., M.J. Cannon, P.J.M. Openshaw, et al. 1987. Cytotoxic T cell specificity for respiratory syncytial virus proteins: fusion protein is an important target antigen. J. Gen. Virol. 68:2177-2182.
93. Piedra, P., A. Jewell, S. Cron, et al. 2003. Correlates of immunity to RSV associated hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. Vaccine 21:3479-3482.
94. Pope, S., E. Brandt, A. Mishra, et al. 2001. IL-13 induces eosinophil recruitment into the lung by an IL-5 and eotaxin-dependent mechanism. J. Allergy Clin. Immunol. 108:594-601.
95. Prince, G., S. Curtis, K. Yim, et al. 2001. Vaccine-enhanced RSV disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine. J. Gen. Virol. 82:2881-2888.
96. Prince, G., B. Jenson, R. Horswood, et al. 1978. The pathogenesis of RSV infection in cotton rats. Am. J. Pathol. 93:771-792.
97. Roman, M., W.J. Calhoun, K.L. Hinton, et al. 1997. RSV infection in infants is associated with predominant Th-2-like response. Am. J. Respir. Crit. Care Med. 156:190-195.
98. Rothenberg, M. 1999. Eotaxin. An essential mediator of eosinophil trafficking into mucosal tissues. Am. J. Respir. Cell. Mol. Biol. 21:291-295.
99. Schlender, J., B. Bessert, U. Buchholz, et al. 2000. Bovine respiratory syncytial virus nonstructural proteins NS1 and NS2 cooperatively antagonize alpha/beta interferon-induced antiviral response. J. Virol. 74:8234-8242.
100. Schmid-Grendelmeier, P., F. Altznauer, B. Fischer, et al. 2002. Eosinophils express functional IL-13 in eosinophilic inflammatory diseases. J. Immunol. 169:1021-1027.
101. Siegrist, C. 2000. Vaccination in the neonatal period and early infancy. Int. Rev. Immunol. 19:195-219.
102. Sigurs, N., R. Bjarnason, F. Sigurbergsson, et al. 2000. Respiratory syncytial virus bronchiolitis is an important risk factor for asthma and allergy at age 7. Am. J. Respir. Crit. Care Med. 161:1501-1507.
103. Singleton, R., N. Etchart, S. Hou, et al. 2003. Inability to evoke a long-lasting protective immune response to RSV infection in mice correlates with ineffective nasal antibody responses. J. Virol. 77:11303-11311.
104. Spann, K., K.-C. Tran, B. Chi, et al. 2004. Suppression of the induction of alpha, beta and lambda interferons by the NS1 and NS2 proteins of human RSV in human epithelial cells and macrophages. J. Virol. 78:4363-4369.
105. + T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine RSV infection. J. Exp. Med. 186: 421-432.
106. Srikiatkhachorn, A., W. Chang, and T. Braciale. 1999. Induction of Th-1 and Th-2 responses by RSV attachment glycoprotein is epitope and major histocompatibility complex independent. J. Virol. 73:6590-6597.
107. Tang, Y.W., and B.S. Graham. 1994. Anti-IL-4-treatment at immunization modulates cytokine expression, reduces illness, and increases cytotoxic T lymphocyte activity in mice challenged with RSV. J. Clin. Invest. 94:1953-1958.
108. Tebbey, P.W., M. Hagen, and G.E. Hancock. 1998. Atypical pulmonary eosinophilia is mediated by a specific amino acid sequence of the attachment (G) protein of RSV. J. Exp. Med. 188:1967-1972.
109. Techaarpornkul, S., N. Barretto, and M. Peeples. 2001. Functional analysis of recombinant respiratory syncytial virus deletion mutants lacking the small hydrophobic and/or attachment glycoprotein gene. J. Virol. 75:6825-6834.
110. Teng, M.N., S.S. Whitehead, and P.L. Collins. 2001. Contribution of the respiratory syncytial virus g glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. Virology 289:283-296.
111. Tripp, R., L. Jones, L. Haynes, et al. 2001. CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat. Immunol. 2:732-738.
112. Tripp, R., D. Moore, A. Barskey, et al. 2002. Peripheral blood mononuclear cells from infants hospitalized because of respiratory syncytial virus infection express T helper-1 and T helper-2 cytokines and CC chemokine messenger RNA. J. Infect. Dis. 185:1388-1394.
113. Tsutsumi, T., K. Matsuda, S. Sone, et al. 1996. RSV-induced cytokine production by neonatal macrophages. Clin. Exp. Immunol. 106:442-446.
114. Valarcher, J., J. Furze, S. Wyld, et al. 2003. Role of alpha/beta interferons in the attenuation and immunogenicity of recombinant bovine respiratory syncytial viruses lacking NS proteins. J. Virol. 77:8426-8439.
115. van der Sande, M., I. Kidd, T. Goetghebuer, et al. 2002. Severe RSV infection in early life is associated with increased type 2 cytokine production in Gambian children. Clin. Exp. Allergy 32:1430-1435.
116. + T cell responses. J. Immunol. 165:6487-6495.
117. Wagner, D., P. Muelenaer, F. Henderson, et al. 1989. Serum immunoglobulin G antibody subclass response to RSV F and G glycoproteins after first, second, and third infections. J. Clin. Microbiol. 27:589-592.
118. Walsh, E., and A. Falsey. 2004. Humoral and mucosal immunity in protection from natural respiratory syncytial virus infection in adults. J. Infect. Dis. 190:373-378.
119. Waris, M.E., C. Tsou, D.D. Erdman, et al. 1996. RSV infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like pattern. J. Virol. 70:2852-2860.
120. Welliver, R., T. Kauk, T. Putnam, et al. 1980. The antibody response to primary and secondary infection with RSV: kinetics of class-specific responses. J. Pediatr. 98:808-813.
121. Young, D., L. Didcock, S. Goodbourn, et al. 2000. Paramyxoviridae use distinct virus-specific mechanisms to cirucmvent the interferon response. Virology 269:383-390.
122. Zhang, Y., B.A. Luxon, A. Casola, et al. 2001. Expression of respiratory syncytial virus-induced chemokine gene networks in lower airway epithelial cells revealed by cDNA microarrays. J. Virol. 75:9044-9058.
123. Zuppan, C., C. Robinson, and C. Langston. 1995. Viral pneumonia in infants and children, pp. 111-153. In: F. Askin, C. Langston, J. Berstein, et al. (eds.), Pulmonary Disease, Vol. 18. Karger, New York.